ライフサイエンスコーパス: lactogenic

1 uence is present in all hormones stimulating lactogenic action and absent in all hormones stimulating

2 wth hormone (hGH) stimulates somatogenic and lactogenic actions through the GH and prolactin (PRL) re

3 isrupts hydrophobic interactions and reduces lactogenic activity between 4.7- and 85-fold with little

4 e differential effects indicate that loss of lactogenic activity is not a result of global mis-foldin

5 We propose the loss of lactogenic activity results from disruption of specific

6 Phe44 is a feature necessary for specifying lactogenic activity.

7 inding protein, but is also activated by non-lactogenic cytokines in many cell types.

8 Cells expressing SL-1 were unable to undergo lactogenic differentiation and became invasive.

9 s of beta-casein, an established reporter of lactogenic differentiation and milk production.

10 ta suggests that the failure of alveolar and lactogenic differentiation due to the loss of Elf5 is me

11 d LY294002 (PI3K-specific inhibitor) blocked lactogenic differentiation in a dose-dependent manner.

12 ach induced STAT5A activation, expression of lactogenic differentiation markers, and lumen formation

13 alyses show that anti-RANKL therapy promotes lactogenic differentiation of tumor cells.

14 Wnt1 and Twist can function as inhibitors of lactogenic differentiation, an effect that could contrib

15 ium, caused precocious STAT5a activation and lactogenic differentiation, and increased cell surface E

16 ogated induction of WDNM1, another marker of lactogenic differentiation.

17 e mice but displayed hallmarks of precocious lactogenic differentiation.

18 development, we were able to demonstrate its lactogenic function in cultured mammary epithelium from

19 smembrane cleavage impaired STAT5A activity, lactogenic gene expression, and lumen formation.

20 kling, the consequent decline in circulating lactogenic hormone concentrations initiates remodeling o

21 We investigated the role of the lactogenic hormone prolactin (PRL) in the regulation of

22 Treatment with the lactogenic hormone prolactin (PRL) in vitro has been sho

23 The lactogenic hormone prolactin (PRL) transcriptionally inc

24 Lactogenic hormone regulation of beta-casein gene expres

25 Prolactin, a lactogenic hormone, binds to two prolactin receptors seq

26 nstrated that AFAP1 responds to prolactin, a lactogenic hormone, by forming a complex with cSrc and b

27 old and 12.5-fold, respectively, whereas the lactogenic hormone, prolactin (PRL) stimulated a 3.5-fol

28 The lactogenic hormone-induced interaction between the proxi

29 n increased cell proliferation and inhibited lactogenic hormone-mediated differentiation as revealed

30 ck C reduced the response of the promoter to lactogenic hormones 84%.

31 ctivation of signal transduction pathways by lactogenic hormones and cell-substratum interactions act

32 ot functionally differentiate in response to lactogenic hormones despite their organization into thre

33 However, the exact mechanisms by which the lactogenic hormones drive beta cell expansion remain unc

34 hin alveolar lumens; systemically, levels of lactogenic hormones fall.

35 To explore potential roles for lactogenic hormones in human fetal development, we exami

36 The potential role of lactogenic hormones in MS is discussed.

37 GADD153 expression was upregulated by the lactogenic hormones insulin and progesterone and associa

38 duction, lactation, and immune function, the lactogenic hormones likely play roles in tissue differen

39 val, and function and mediated mainly by the lactogenic hormones prolactin (PRL) and placental lactog

40 a transgenic mouse model engineered so that lactogenic hormones stimulate a sustained increase in eI

41 mouse mammary GPT gene is stimulated by the lactogenic hormones, insulin, glucocorticoid, and prolac

42 This study explores the role of lactogenic hormones, prolactin (PRL) and placental lacto

43 In the presence of lactogenic hormones, recombinant expression of caveolin-

44 dered receptor binding for each of the three lactogenic hormones.

45 mber, secretory capacity, and sensitivity to lactogenic hormones.

46 the milk protein beta-casein in response to lactogenic hormones.

47 iates in response to a basement membrane and lactogenic hormones.

48 lveolar PCD even in the presence of systemic lactogenic hormones.

49 ultivation with the combination of the three lactogenic hormones.

50 se was disrupted in the presence of systemic lactogenic hormones: (i) sealing of the teats, (ii) mamm

51 ng of ordered binding to include three human lactogenic hormones: prolactin, growth hormone, and plac

52 be a promising strategy to prolong maternal lactogenic immunity against postweaning infections.

53 for maternal rotavirus vaccination to boost lactogenic immunity and transfer passive antibodies to t

54 was imaged optically in real time following lactogenic induction.

55 eIF4E abundance in stem/progenitor cells of lactogenic mammary epithelium during successive pregnanc

56 tudies have broad implications for using the lactogenic microenvironment as a paradigm to discover ne

57 l model to study the protective effects of a lactogenic microenvironment on mammary tumor onset and p

58 structures, either free or bound to a single lactogenic or somatotrophic receptor, shows binding is a

59 hGH structure are unique when binding either lactogenic or somatotrophic receptors and they influence

60 Human growth hormone (hGH) binds lactogenic or somatotrophic receptors, creating active h

61 east cancers, consistent with a constitutive lactogenic phenotype.

62 e to feedback inhibition of prolactin by the lactogenic properties of the hGH transgene.

63 either alanine or leucine partially restored lactogenic receptor binding affinity, which correlated w

64 rophobic side chain of Phe44 is required for lactogenic receptor binding and activation but is unnece

65 on of Phe44 reduced binding affinity for the lactogenic receptor, resulting in a reduced activation.

66 and an obligate mediator of mammopoietic and lactogenic signaling.